

CONTENTS

Preface	v
Introduction <i>H. Koyama and M. Umeda</i>	vii

RAISING OF USEFUL CELL LINES

CULTIVATION OF HUMAN MYELOMA CELLS

. *M. Namba, K. Nishitani, F. Hyodoh, F. Fukushima,
T. Ohtsuki, N. Inoue, K. Miyamoto, K. Imai,
K. Nose, J. Minowada, and T. Kimoto* 3

I. Characteristics of our established cell lines	4
II. Present problems and prospects for the future	10
Summary	13

CHARACTERISTICS AND UTILITY OF A PANEL OF 93 HUMAN LEUKEMIA-LYMPHOMA CELL LINES *J. Minowada* 17

I. Establishment, characterization, and cryopreservation	18
--	----

II. Clinical utility, significance, and implication 21
III. Theoretical utility, significance, and implication 25
Summary 29

STRUCTURE AND FUNCTION OF E1A GENES OF ADENOVIRUS
TYPE 12—APPLICATION OF E1A FOR RAISING A USEFUL
MAMMALIAN CELL LINE

. *K. Onodera, Y. Etoh, S. Takano,
H. Morioka, and H. Shibai* 37
I. Characteristics of cells in which the E1A gene has been
introduced 39
II. Introduction of the E1A gene into mammalian cells 42
III. Further information on the function of the E1A gene 47
Summary 50

A ROLE FOR EPSTEIN-BARR VIRUS (EBV) IN IMMORTALIZATION
OF PRIMATE EPITHELIAL CELLS *B.E. Griffin* 55

I. Establishment and characterization of immortalized epithelial
cells 57
II. Potential usefulness of EBV p31-induced monkey (and human)
cell lines 63
Summary 64

EXPLOITATION OF MAMMALIAN CELL VECTORS

L FACTOR, A POTENTIALLY USEFUL PLASMID VECTOR FOR
MAMMALIAN CELLS

. *H. Uehara, T. Kusano, H. Saito, K. Segawa, and M. Oishi* 71
I. Discovery and characteristics of L factors in a subline of L cells
. 72
II. Replication and the expression of L factors 80
III. L factor as a plasmid 84
IV. Application of L factors 85
Summary 86

DEVELOPMENT AND APPLICATION OF A VECTOR SYSTEM
THAT PERMITS CLONING OF cDNA's ON THE BASIS OF THEIR
EXPRESSION IN MAMMALIAN CELLS

	<i>H. Okayama</i>	91
I. High-efficiency cloning of full-length cDNA		92
II. The pcD expression vector		94
III. The LambdaNMT transducing vector		96
IV. An attempt to improve cDNA library transduction		98
V. Application		100
Summary		101

PRODUCTION OF BIOLOGICALS AND THE SAFETY PROBLEMS

PRODUCTION AND DEVELOPMENT OF BIOLOGICALS DERIVED
FROM RECOMBINANT-DNA MAMMALIAN CELL CULTURES

	<i>J. Obijeski</i>	105
I. Construction of mammalian cell vectors by recombinant DNA technique		106
II. Immunization by recombinant vaccine		108
III. Use of continuous cell lines for the production of biologicals		110
IV. Cell characterization		110
V. Validated production procedure and assurance of the purity and safety of products		111
VI. Problems of endogenous viruses		114
Summary		115

PRODUCTION OF MONOCLONAL ANTIBODIES WITH HUMAN-
HUMAN HYBRIDOMAS IN SERUM-FREE CULTURE AND ITS
PROSPECTS FOR MEDICAL USE

	<i>H. Murakami</i>	119
I. Preparation of fusion partner cell lines		119
II. Characteristics of a fusion partner cell line, HO-323		120
III. Serum-free culture of human-human hybridomas		122
IV. Monoclonal antibodies specific to cancer cells		127
V. Characterization of cancer specific antigens		132

VI. Multifunctional antibody	133
Summary	135

MASS MAMMALIAN CELL CULTURE

.	<i>N.B. Finter, M.D. Johnston, G.D. Ball,</i>	
	<i>K. Fantes, and K. Pullen</i>	139
I. Wellcome and interferons		140
II. Wellcome's suspended cell technology		141
III. Interferon production		142
IV. Acceptability of lymphoblastoid interferon		143
V. Clinical studies		144
VI. Other applications of Wellcome's mass mammalian cell culture technology		144
Summary		145

PRODUCTION AND CHARACTERIZATION OF HUMAN INTERFERON-GAMMA AND OTHER SUBSTANCES PRODUCED BY GENETICALLY ENGINEERED MAMMALIAN CELLS

.	<i>E. Sano, T. Sudo, K. Okano, R. Sawada,</i>	
	<i>M. Ito, M. Naruto, M. Iizuka, and S. Kobayashi</i>	149
I. Construction of expression plasmids		150
II. Long-term cultivation of the recombinant C127 cells producing IFN- γ or IL-2		151
III. Long-term cultivation of recombinant CHO cells producing IFN- γ or IL-2		155
IV. Physicochemical properties of IFN- γ produced by recombinant CHO and C127 cells		158
Summary		161

THE SAFETY OF PRODUCTS DERIVED FROM CONTINUOUS CELL LINES

.	<i>J.C. Petriccioni</i>	165
I. Current issues		167
II. Biotechnology		172
III. WHO activities		173
IV. Conclusions		176
Summary		178

CONTENTS

xvii

Author Index 181
Subject Index 183